Company: BSX
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0000885725-25-000050
Chunk: 43

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 1
Chunk 43
---
2,649 

Refer to notes to the unaudited consolidated financial statements. Amounts may not add due to rounding.

7

Table of Contents

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(SUPPLEMENTAL INFORMATION)

Nine Months Ended September 30,(in millions)20252024Supplemental InformationStock-based compensation expense$228 $197 Fair value of contingent consideration recorded in purchase accounting258 29 Right-of-use assets obtained in exchange for finance lease obligations195 — 

As of September 30,(in millions)20252024Reconciliation to amounts within the unaudited consolidated balance sheets:Cash and cash equivalents$1,275 $2,502 Restricted cash and restricted cash equivalents included in Other current assets98 70 Restricted cash equivalents included in Other long-term assets103 78 Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period$1,476 $2,649 

Refer to notes to the unaudited consolidated financial statements. Amounts may not add due to rounding.

8

Table of Contents

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE A – BASIS OF PRESENTATION The accompanying unaudited consolidated financial statements of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X, and they do not include all of the information and footnotes required by GAAP for complete financial statements. When used in this report, the terms, "we," "us," "our," and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three and nine months ended September 30, 2025 are not necessarily indicative of the results that may be expected for the year ending December 31, 2025. Accordingly, our unaudited consolidated financial statements and footnotes thereto should be read in conjunction with our audited consolidated financial statements and footnotes thereto included in Item 8 of our most recent Annual Report on Form 10-K. The accompanying unaudited consolidated financial statements include the accounts of the Company's wholly owned- subsidiaries and entities for which we have a controlling